TRML · Insider Trading
Tourmaline Bio, Inc. Common Stock
Every open-market purchase and sale reported by TRML officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-10-28 | Caley Castelein | Director | U | −947,936 | — |
| 2025-10-28 | Mark McDade | Director | U | −742,209 | — |
| 2025-10-28 | W Bradford Middlekauff | CBO, GC and Secretary | MIXED | −69,201 | — |
| 2025-10-28 | Sapna Srivastava | Director | U | −518 | — |
| 2025-10-28 | Susan Dana Jones | Chief Technology Officer | MIXED | −22,934 | — |
| 2025-10-28 | Clay B Siegall | Director | D | −51,800 deriv. | — |
| 2025-10-28 | Parvinder Thiara | Director | U | −83,782 | — |
| 2025-10-28 | Aaron Kantoff | Director | U | −88,281 | — |
| 2025-10-28 | Ryan F. Robinson | CFO | U | −14,366 | — |
| 2025-10-28 | Sandeep Chidambar Kulkarni | CEO | MIXED | −762,051 | — |
| 2025-10-28 | Kevin Bruce Johnson | Chief Regulatory Officer | MIXED | −51,584 | — |
| 2025-10-24 | Ryan F. Robinson | CFO | M | +14,366 | +$199.97K |
| 2025-10-24 | Aaron Kantoff | Director | G | −5,000 | — |
| 2025-10-24 | Sandeep Chidambar Kulkarni | CEO | M | +25,316 | +$200.00K |
| 2025-10-17 | Kevin Bruce Johnson | Chief Regulatory Officer | G | −6,250 | — |
| 2025-10-17 | Caley Castelein | Director | G | −522 | — |
| 2025-09-09 | Aaron Kantoff | Director | M | +47,890 | +$99.53K |
| 2025-06-06 | Caley Castelein | Director | A | +16,800 deriv. | — |
| 2025-06-06 | Aaron Kantoff | Director | A | +16,800 deriv. | — |
| 2025-06-06 | Sapna Srivastava | Director | A | +16,800 deriv. | — |
| 2025-06-06 | Mark McDade | Director | A | +16,800 deriv. | — |
| 2025-06-06 | Parvinder Thiara | Director | A | +16,800 deriv. | — |
| 2025-06-06 | Clay B Siegall | Director | A | +16,800 deriv. | — |
| 2025-02-04 | Sandeep Chidambar Kulkarni | CEO | A | +226,000 deriv. | — |
| 2025-01-29 | Kevin Bruce Johnson | Chief Regulatory Officer | A | +58,000 deriv. | — |
| 2025-01-29 | Ryan F. Robinson | Chief Financial Officer | A | +58,000 deriv. | — |
| 2025-01-29 | Susan Dana Jones | Chief Technology Officer | A | +58,000 deriv. | — |
| 2025-01-29 | W Bradford Middlekauff | CBO, GC and Secretary | A | +58,000 deriv. | — |
| 2024-08-22 | Sandeep Chidambar Kulkarni | CEO | Buy | +1,779 | +$26.42K |
| 2024-08-20 | Sandeep Chidambar Kulkarni | CEO | Buy | +5,221 | +$72.00K |
| 2024-06-27 | Ryan F. Robinson | Chief Financial Officer | A | +76,400 deriv. | — |
| 2024-06-07 | Parvinder Thiara | Director | A | +10,000 deriv. | — |
| 2024-06-07 | Caley Castelein | Director | A | +10,000 deriv. | — |
| 2024-06-07 | Mark McDade | Director | A | +10,000 deriv. | — |
| 2024-06-07 | Sapna Srivastava | Director | A | +10,000 deriv. | — |
| 2024-06-07 | Aaron Kantoff | Director | A | +10,000 deriv. | — |
| 2024-06-07 | Clay B Siegall | Director | A | +15,000 deriv. | — |
| 2024-01-31 | Mark McDade | Director | Buy | +100,000 | +$3.25M |
| 2023-12-15 | Clay B Siegall | Director | A | +20,000 deriv. | — |
| 2023-11-20 | Parvinder Thiara | Director | Buy | +1,000 | +$17.31K |
| 2023-11-20 | Sandeep Chidambar Kulkarni | CEO | Buy | +4,000 | +$67.96K |
| 2023-10-27 | Caley Castelein | Director | Buy | +20,000 | +$280.58K |
| 2023-10-26 | Parvinder Thiara | Director | Buy | +7,000 | +$77.54K |
| 2023-10-26 | Aaron Kantoff | Director | Buy | +7,500 | +$88.95K |
| 2023-10-26 | Sandeep Chidambar Kulkarni | CEO | Buy | +9,650 | +$110.91K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Sandeep Chidambar Kulkarni | CEO | 30,387 | $1.46M |
| W Bradford Middlekauff | CBO, GC and Secretary | 8,213 | $394.06K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TRML quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.